Trial · NCT04413617
Results by group440
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 440
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12 | PF-06650833 400mg MR + Tofacitinib 11mg MR | -2.65 | 90% Confidence Interval -2.84 to -2.46 | Units on a scale | |
| Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12 | PF-06650833 400mg MR + PF-06651600 100mg | -2.35 | 90% Confidence Interval -2.54 to -2.15 | Units on a scale | |
| Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12 | Tofacitinib 11mg MR | -2.30 | 90% Confidence Interval -2.49 to -2.11 | Units on a scale | |
| Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12 | PF-06651600 100mg | -2.20 | 90% Confidence Interval -2.43 to -1.98 | Units on a scale | |
| Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12 | PF-06650833 400mg MR | -1.82 | 90% Confidence Interval -2.04 to -1.60 | Units on a scale | |
| DAS28-CRP Remission (<2.6) Rates at Week 24 | PF-06650833 400mg MR + Tofacitinib 11mg MR | 40.8 | 90% Confidence Interval 32.6 to 48.7 | Percentage of participants | |
| DAS28-CRP Remission (<2.6) Rates at Week 24 | PF-06650833 400mg MR + PF-06651600 100mg | 31.3 | 90% Confidence Interval 24.1 to 39.8 | Percentage of participants | |
| DAS28-CRP Remission (<2.6) Rates at Week 24 | Tofacitinib 11mg MR | 24.0 | 90% Confidence Interval 17.1 to 31.8 | Percentage of participants | |
| DAS28-CRP Remission (<2.6) Rates at Week 24 | PF-06651600 100mg | 22.4 | 90% Confidence Interval 14.8 to 31.3 | Percentage of participants | |
| DAS28-CRP Remission (<2.6) Rates at Week 24 | PF-06650833 400mg MR | 11.8 | 90% Confidence Interval 6.7 to 19.3 | Percentage of participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs | Tofacitinib 11mg MR | All-causality TEAEs | 60 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs | PF-06651600 100mg | All-causality TEAEs | 42 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs | PF-06650833 400mg MR | All-causality TEAEs | 38 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs | PF-06650833 400mg MR + Tofacitinib 11mg MR | All-causality TEAEs | 51 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs | PF-06650833 400mg MR + PF-06651600 100mg | All-causality TEAEs | 55 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs | Tofacitinib 11mg MR | Treatment-related TEAEs | 15 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs | PF-06651600 100mg | Treatment-related TEAEs | 17 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs | PF-06650833 400mg MR | Treatment-related TEAEs | 13 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs | PF-06650833 400mg MR + Tofacitinib 11mg MR | Treatment-related TEAEs | 20 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs | PF-06650833 400mg MR + PF-06651600 100mg | Treatment-related TEAEs | 25 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04413617/results